A citation-based method for searching scientific literature

Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao, Mingshan Niu, Rutong Yu. J Exp Clin Cancer Res 2019
Times Cited: 47







List of co-cited articles
707 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
38

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
36

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu,[...]. Neuro Oncol 2015
108
34

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
29

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
25

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.
Igor Makhlin, Ryan D Salinas, Daniel Zhang, Fadi Jacob, Gou-Li Ming, Hongjun Song, Deeksha Saxena, Jay F Dorsey, MacLean P Nasrallah, Jennifer Jd Morrissette,[...]. CNS Oncol 2019
21
52


Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Hua-Fu Zhao, Jing Wang, Wei Shao, Chang-Peng Wu, Zhong-Ping Chen, Shing-Shun Tony To, Wei-Ping Li. Mol Cancer 2017
144
19

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
Arnab Chakravarti, Meihua Wang, H Ian Robins, Tim Lautenschlaeger, Walter J Curran, David G Brachman, Christopher J Schultz, Ali Choucair, Marisa Dolled-Filhart, Jason Christiansen,[...]. Int J Radiat Oncol Biol Phys 2013
98
19

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.
Frank B Furnari, Timothy F Cloughesy, Webster K Cavenee, Paul S Mischel. Nat Rev Cancer 2015
235
19

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz, Carmen Balañá, Miguel Gil-Gil, Gaspar Reynés, Óscar Gallego, María Martínez-García, Elena Vicente, María Quindós, Raquel Luque,[...]. Neuro Oncol 2017
60
17

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
528
17

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Raghupathy Vengoji, Muzafar A Macha, Rama Krishna Nimmakayala, Satyanarayana Rachagani, Jawed A Siddiqui, Kavita Mallya, Santhi Gorantla, Maneesh Jain, Moorthy P Ponnusamy, Surinder K Batra,[...]. J Exp Clin Cancer Res 2019
48
17

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskil Eskilsson, Gro V Røsland, Gergely Solecki, Qianghu Wang, Patrick N Harter, Grazia Graziani, Roel G W Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletic. Neuro Oncol 2018
132
17

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
Zhenyi An, Ozlem Aksoy, Tina Zheng, Qi-Wen Fan, William A Weiss. Oncogene 2018
227
17

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
17

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Jayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, Yangming Ou, Kyrre E Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, John G Evans, Jorg Dietrich,[...]. J Neurooncol 2017
44
15

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
David A Reardon, Morris D Groves, Patrick Y Wen, Louis Nabors, Tom Mikkelsen, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E McLendon, A Benjamin Suttle,[...]. Clin Cancer Res 2013
71
14

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
David M Peereboom, Dale R Shepard, Manmeet S Ahluwalia, Cathy J Brewer, Neeraj Agarwal, Glen H J Stevens, John H Suh, Steven A Toms, Michael A Vogelbaum, Robert J Weil,[...]. J Neurooncol 2010
140
14

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Joon H Uhm, Karla V Ballman, Wenting Wu, Caterina Giannini, J C Krauss, Jan C Buckner, C D James, Bernd W Scheithauer, Robert J Behrens, Patrick J Flynn,[...]. Int J Radiat Oncol Biol Phys 2011
117
14

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor,[...]. Cancer Discov 2014
14

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Michael D Prados, Susan M Chang, Nicholas Butowski, Rebecca DeBoer, Rupa Parvataneni, Hannah Carliner, Paul Kabuubi, Jennifer Ayers-Ringler, Jane Rabbitt, Margaretta Page,[...]. J Clin Oncol 2009
269
14

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Elizabeth R Gerstner, April F Eichler, Scott R Plotkin, Jan Drappatz, Colin L Doyle, Lei Xu, Dan G Duda, Patrick Y Wen, Rakesh K Jain, Tracy T Batchelor. J Neurooncol 2011
71
14

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Tracy T Batchelor, Paul Mulholland, Bart Neyns, L Burt Nabors, Mario Campone, Antje Wick, Warren Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn S Ashby,[...]. J Clin Oncol 2013
365
14

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, J-F Baurain, L D'Hondt, T Strauven, C Chaskis, P In't Veld,[...]. Ann Oncol 2009
155
14

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, Roger E McLendon, Jennifer Marcello, James E Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N Rich, Julie A Norfleet,[...]. Neuro Oncol 2010
161
14

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
14

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Nicholas Brown, Catherine McBain, Stephen Nash, Kirsten Hopkins, Paul Sanghera, Frank Saran, Mark Phillips, Fiona Dungey, Laura Clifton-Hadley, Katharina Wanek,[...]. PLoS One 2016
29
20

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Xuejiao Liu, Yulong Chong, Yiming Tu, Ning Liu, Chenglong Yue, Zhenglei Qi, Huize Liu, Yao Yao, Hongmei Liu, Shangfeng Gao,[...]. J Hematol Oncol 2016
49
12

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
David A Reardon, Annick Desjardins, James J Vredenburgh, Sridharan Gururangan, Allan H Friedman, James E Herndon, Jennifer Marcello, Julie A Norfleet, Roger E McLendon, John H Sampson,[...]. J Neurooncol 2010
161
12

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Brian Thiessen, Clinton Stewart, Ming Tsao, Suzanne Kamel-Reid, Paula Schaiquevich, Warren Mason, Jacob Easaw, Karl Belanger, Peter Forsyth, Lynn McIntosh,[...]. Cancer Chemother Pharmacol 2010
130
12

Targeting cellular pathways in glioblastoma multiforme.
Joshua R D Pearson, Tarik Regad. Signal Transduct Target Ther 2017
148
12

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
12

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
12

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Donald M O'Rourke, MacLean P Nasrallah, Arati Desai, Jan J Melenhorst, Keith Mansfield, Jennifer J D Morrissette, Maria Martinez-Lage, Steven Brem, Eileen Maloney, Angela Shen,[...]. Sci Transl Med 2017
816
12

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
12


Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Gustavo Chagoya, Shawn G Kwatra, Cory W Nanni, Callie M Roberts, Samantha M Phillips, Sarah Nullmeyergh, Samuel P Gilmore, Ivan Spasojevic, David L Corcoran, Christopher C Young,[...]. Oncotarget 2020
17
35

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Igor Vivanco, H Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes, Phioanh Leia Nghiemphu, Sara Kubek, Barbara Oldrini, Milan G Chheda, Nicolas Yannuzzi,[...]. Cancer Discov 2012
229
12

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Eudocia Q Lee, Thomas J Kaley, Dan G Duda, David Schiff, Andrew B Lassman, Eric T Wong, Tom Mikkelsen, Benjamin W Purow, Alona Muzikansky, Marek Ancukiewicz,[...]. Clin Cancer Res 2015
52
10

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Peter Ballard, James W T Yates, Zhenfan Yang, Dong-Wan Kim, James Chih-Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist,[...]. Clin Cancer Res 2016
420
10

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Eric Raymond, Alba A Brandes, Christian Dittrich, Pierre Fumoleau, Bruno Coudert, Paul M J Clement, Marc Frenay, Roy Rampling, Roger Stupp, Johan M Kros,[...]. J Clin Oncol 2008
165
10

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, Minesh P Mehta, Susan M Chang, Nicholas A Butowski, Lisa M Deangelis, Lauren E Abrey, Wei-Ting Zhang, Michael D Prados,[...]. Neuro Oncol 2010
132
10

Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment
Farina Hanif, Kanza Muzaffar, Kahkashan Perveen, Saima M Malhi, Shabana U Simjee. Asian Pac J Cancer Prev 2017
398
10

Fibroblast Growth Factor Receptor Functions in Glioblastoma.
Ana Jimenez-Pascual, Florian A Siebzehnrubl. Cells 2019
48
10

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
10

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Martin J van den Bent, Alba A Brandes, Roy Rampling, Mathilde C M Kouwenhoven, Johan M Kros, Antoine F Carpentier, Paul M Clement, Marc Frenay, Mario Campone, Jean-Francois Baurain,[...]. J Clin Oncol 2009
401
10

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Prakash Chinnaiyan, Minhee Won, Patrick Y Wen, Amyn M Rojiani, Maria Werner-Wasik, Helen A Shih, Lynn S Ashby, Hsiang-Hsuan Michael Yu, Volker W Stieber, Shawn C Malone,[...]. Neuro Oncol 2018
76
10

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
10

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.
Shucheng Yin, Ada Girnita, Thomas Strömberg, Zahidul Khan, Sandra Andersson, Huiyuan Zheng, Christer Ericsson, Magnus Axelson, Monica Nistér, Olle Larsson,[...]. Neuro Oncol 2010
67
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.